

ASX Release

21 February 2023

Placement of Shortfall from Entitlement Offer

MELBOURNE, 21 February 2023: Anatara Lifesciences Limited (ASX: ANR, 'Anatara' or 'the Company'), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to advise that it has today issued the remaining 8,794,051 fully paid ordinary shares (Shares) at an issue price of \$0.035 per Share and 4,397,026 New Options (exercisable at \$0.07 and expiring on 11 December 2025) under the Shortfall Offer pursuant to the entitlement issue prospectus dated 21 October 2022 (Entitlement Offer Prospectus).

The Shares under the Shortfall Offer were taken up by Institutional and Sophisticated Investors, raising an additional \$307,791. This placement takes the total Shares issued under the Entitlement Issue Prospectus to 23,785,207 Shares and 11,892,604 Options, raising total funds of \$832,482 before costs.

Executive Chairman, Dr David Brookes, said, "We are pleased with the support from existing shareholders who have participated in the Placement of this shortfall. The additional funding enhances the Company's financial position to pursue clinical and corporate initiatives."

The Shares were issued under exception 3 of Listing Rule 7.2 and therefore will not occupy the Company's 15% placement capacity pursuant to Listing Rule 7.1.

Taylor Collison Limited acted as Lead Manager and Candour Advisory Pty Ltd acted as Advisor to the Company.

Release authorised by: The Board of Anatara Lifesciences Limited

For more information, please contact:

Dr. David Brookes

Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel

Candour Advisory – Investor Relations
+61 (0) 408 326 367
dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for human and animal health. Anatara is focused on building a pipeline of human

Anatara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

Suite 101, 55 Flemington Rd, North Melbourne, VIC 3051, Australia

Email info@anatara.com | Website anataralifesciences.com

gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anantara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

Suite 101, 55 Flemington Rd, North Melbourne, VIC 3051, Australia

Email info@anantara.com | Website anataralifesciences.com

